{"id":126,"date":"2018-08-28T04:20:29","date_gmt":"2018-08-28T04:20:29","guid":{"rendered":"https:\/\/www.ladrxcorp.com\/?page_id=126"},"modified":"2022-09-26T16:28:13","modified_gmt":"2022-09-26T16:28:13","slug":"investor-relations","status":"publish","type":"page","link":"https:\/\/www.ladrxcorp.com\/investor-relations\/","title":{"rendered":"Investor Relations"},"content":{"rendered":"<div id=\"cs-content\" class=\"cs-content\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Investor Relations &#8211; OverviewLadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs. LadRx has a milestone and royalty agreement with Orphazyme A\/S (Nasdaq &#8211; &#8220;ORPH&#8221;) &#8230; <a href=\"https:\/\/www.ladrxcorp.com\/investor-relations\/\" class=\"more-link\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-layout-sidebar-content.php","meta":[],"_links":{"self":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages\/126"}],"collection":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/comments?post=126"}],"version-history":[{"count":10,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages\/126\/revisions"}],"predecessor-version":[{"id":1526,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages\/126\/revisions\/1526"}],"wp:attachment":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/media?parent=126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}